Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

Cerebrolysin vs PE-22-28

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

Cerebrolysin: CPE-22-28: D
AttributeCerebrolysinPE-22-28
CategoryNootropic / NeuroprotectiveNootropic / Neuroprotective
Evidence RatingCPhase I–II Clinical TrialsDPreclinical Only
Clinical StatusApproved as prescription drug in 50+ countries (Austria, Russia, China, South Korea, and others). Not FDA-approved. Over 150 clinical trials with >7,000 patients.Preclinical tool compound only. No clinical trials. No regulatory evaluation.
MechanismCerebrolysin provides multimodal neuroprotection through several pathways: it enhances neurogenesis and neuroplasticity via activation of PI3K/AKT and Sonic Hedgehog (Shh) signaling, promotes synaptic remodeling through CREB phosphorylation and BDNF-like activity, inhibits calpain-mediated neuronal ...PE-22-28 blocks the TREK-1 two-pore-domain potassium channel (KCNK2/K2P2.1), which is widely expressed in the brain. TREK-1 knockout mice display a depression-resistant phenotype, suggesting that TREK-1 blockade may have antidepressant effects. PE-22-28 is a more potent and shorter analog of spadin ...
Half-Life
Bioavailability
Molecular Weight
WADA StatusNot ListedNot Listed
Research Half-Life
Key Use Cases
  • Cognitive Enhancement
  • Antidepressant Research
  • Ion Channel Research
Safety Concerns
  • Generally well-tolerated in clinical trials
  • Common: dizziness, headache, injection site reactions
  • Rare: agitation, fever, flu-like symptoms
  • No human safety data exist
  • Mouse studies at antidepressant-effective doses did not report overt toxicity
  • TREK-1 channels are expressed in heart, vasculature, and GI tract — potential for off-target effects
Contraindications
  • Epilepsy or history of seizures
  • Severe renal impairment
  • Known allergy to porcine-derived products
  • Pregnancy and breastfeeding
  • Not for human use (research compound only)
  • No established contraindications due to absence of any clinical data
  • Theoretical cardiac risk due to TREK-1 expression in cardiomyocytes
Regulatory (US)Not FDA-approved. No IND application. Cannot be legally prescribed.Not FDA-evaluated. Research tool compound. Sold by some peptide suppliers as a research chemical.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationCerebrolysinPE-22-28
Purity Standard≥98%≥98%
CAS NumberN/AN/A
Molecular FormulaN/AN/A
Available Formats60mg10mg
Batch COAs Published
Stock StatusOut of stockOut of stock

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.